New data support early use of newer DMTs in children with RRMS, say specialists

New study data on the use of newer versus injectable disease modifying therapies (DMTs) in children with relapsing-remitting multiple sclerosis (RRMS) have led to calls for a shift in practice.

Dr Omar Abdel-Mannan from Great Ormond Street Hospital in London, UK, said the improved outcomes seen with the use of newer DMTs add to the evidence supporting their first-line use in pediatric MS.

Presenting at the ICNA/CNS 2020 virtual conference, Dr Abdel-Mannan reported findings from a real-world observational study involving 7 centers in the UK, and a total of 103 patients with a diagnosis of RRMS who were treated with DMTs between 2012 and 2018.